FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study†

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study†

EAGLE was a randomized, multicenter phase III study which evaluated the superiority of bevacizumab 10 mg/kg plus FOLFIRI compared with bevacizumab 5 mg/kg plus FOLFIRI in patients with mCRC previously treated with first-line bevacizumab plus an oxaliplatin-based regimen. The results suggest that the...

Full description

Bibliographic Details
Main Authors: Iwamoto, S., Takahashi, T., Tamagawa, H., Nakamura, M., Munemoto, Y., Kato, T., Hata, T., Denda, T., Morita, Y., Inukai, M., Kunieda, K., Nagata, N., Kurachi, K., Ina, K., Ooshiro, M., Shimoyama, T., Baba, H., Oba, K., Sakamoto, J., Mishima, H.
Format: Online
Language:English
Published: Oxford University Press 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478977/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478977/

Similar Items